Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 1, 2001, Pages 25-32

  Lelouet H ^a   Bechtel, Y C ^a   Paintaud, G ^a   Brientini, M P ^a   Miguet, J P ^a   Bechtel, P R ^a  

^a Faculté de Médecine   (France)

Author keywords

Caffeine; Metabolism; Primary biliary cirrhosis

Indexed keywords

CAFFEINE; XANTHINE;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; URINARY EXCRETION;

EID: 0035150069     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39025     Document Type: Article

References (30)

1. Products of metabolism of caffeine
2. The pharmacology of caffeine
3. A population and family study of N-acetyltransferase using caffeine urinary metabolites
4. Human arylamine N-acetyltransferase genes: Isolation, chromosal localization and functional expression
5. Pharmacokinetics of caffeine
6. Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens
7. Survey of the human acetylator polymorphism in spontaneous disorders
8. Drug metabolism in liver disease: Activity of microsomal metabolizing enzymes
9. Impaired delayed hypersensitivity in primary biliary cirrhosis
10. Evaluation of caffeine as a test drug for CYP1A2, NAT-2, CYP2E1 phenotyping in man by in vivo versus in vitro correlations
11. Differential alteration of cytochrome P450 proteins in livers from patients with severe chronic liver diseases
12. Variability in caffeine metabolism
13. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA expressed human CYP1A2 and CYP2E1
14. Primary biliary cirrhosis
15. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2 N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping
16. Drug acetylation in liver disease
17. Clinical pharmacokinetics in patients with liver disease
18. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: An update
19. A routine method for the establishment of permanent growing lymphoblastoid
20. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis
21. Effects of liver diseases on drug metabolism
22. Drug and the liver
23. Effects of liver disease on pharmacokinetics: An update
24. Caffeine metabolism in patients with chronic liver disease
25. Caffeine urinary metabolite ratios as markers of enzyme activity: A theoretical assessment
26. Primary biliary cirrhosis: Chronic non-suppurative destructive cholangitis
27. Primary biliary cirrhosis
28. Caffeine clearance and biotransformation in patients with chronic liver disease
29. The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease
30. Antipyrine kinetics in patients with primary biliary cirrhosis